Collegium Pharmaceutical (COLL) Retained Earnings (2014 - 2026)

Collegium Pharmaceutical's Retained Earnings history runs 13 years deep, the most recent figure standing at -$86.6 million for Q1 2026.

• In Q1 2026, Retained Earnings rose 46.38% year-over-year to -$86.6 million; the TTM figure through Mar 2026 stood at -$86.6 million (up 46.38% YoY), while the FY2025 annual figure was $319000.0, up 100.19% from the prior year.
• Retained Earnings was -$86.6 million for Q1 2026 at Collegium Pharmaceutical, down from $319000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $337000.0 in Q2 2025 to a low of -$298.8 million in Q1 2023.
• Historically, Retained Earnings has averaged -$172.3 million across 5 years, with a median of -$185.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings slumped 1171521.43% in 2024, then surged 100.19% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$281.3 million in 2022, then surged by 100.0% to $14000.0 in 2023, then plunged by 1171521.43% to -$164.0 million in 2024, then soared by 100.19% to $319000.0 in 2025, then tumbled by 27257.68% to -$86.6 million in 2026.
• The last three Retained Earnings figures came in at -$86.6 million (Q1 2026), $319000.0 (Q4 2025), and $292000.0 (Q3 2025), per Business Quant data.